成果報告書詳細
管理番号20130000000148
タイトル*平成24年度中間年報 「IT融合による新社会システムの開発・実証プロジェクト (ヘルスケア分野)角膜再生医療の普及のための診断・治療IT支援システム開発・ビジネスモデル実証事業」
公開日2014/6/14
報告書年度2012 - 2012
委託先名国立大学法人大阪大学 株式会社ニデック 株式会社ジャパン・ティッシュ・エンジニアリング
プロジェクト番号P12009
部署名バイオテクノロジー・医療技術部
和文要約
英文要約Title:Validation project to develop business model with IT assisted diagnosis and treatment system for the dissemination of corneal regenerative medicine
Validation project to develop business model with IT assisted diagnosis and treatment system for the dissemination of corneal regenerative medicine
Abstract
Corneal regenerative medicine using oral mucosal cell sheet has attracted considerable attention as a next generational medical treatment of incredible corneal diseases (K. Nishida et al, N Engl J Med 2004; 351:1187-96). Since oral mucosal cells are collected from the patient's owns oral mucosa, the cell sheet is free from immunological rejection as well as donor lacking situations. Even though there are attractive advantages of the cell sheet treatment; however, since the corneal regenerative medicine is managed by cornea experts of ophthalmologist and professional cell sheet manufactures, the number of operation of corneal regenerative medicine is still limited. Therefore, developing alternative strategy to spreading the operation of the corneal regenerative medicine is strongly desired. In this project, we will present the novel business model to disseminate the corneal regenerative medicine using oral mucosal cell sheet. The purpose of this project is to investigate whether the analogical knowledge and skills of experts for the corneal regenerative medicine convert to the objective and simple digital data contents using newly developed IT-based diagnosis and treatment systems. As a result, the corneal regenerative medicine using cell sheet widely managed by non-experts could be expected.
Mission and achievements in terms of 2012
1. Development of the IT-assisted diagnosis system and databasing
Before the corneal cell sheet transplantation, estimation of pathological findings such as cornea neovascularization, hyperemia of conjunctive, epithelial defect of cornea, opacity, and edema in the recipient cornea is very important. Therefore, first we investigated whether the analogical pathological findings of corneal diseases can be interpreted as the simplified digital data contents. As a result, it was revealed that the neovascular vessel and epithelial defect were described and measureable as digital data contents by our newly developed system (the content is confidential for patent applications).
2. Development of the IT-assisted management system of corneal cell sheet
The quality of corneal cell sheet was assessed by measuring the several physiochemical conditions. A surface morphology of the cell sheets was observed day by day using optical microscopy. During this period, electric resistances of the cell sheet were measured as the Trans Epithelial Electric Resistance (TEER). Though those data is useful to evaluate the quality of the cell sheet for the manufacture experts, but is not enough for non-expert. In this time, we added the new parameter to evaluate the quality of cell sheets. To solve these problems, the level of chemical compounds detected during cell sheet incubation was monitored day by day. Key compounds to monitor are as follows; glutamic acid, glutamine, glucose, lactic acid ion, and ammonium ion. We found that we can figure out the good condition of cell sheet during incubation by collecting the information of these chemical compounds as digital data contents.
Conclusion
The analogical expertise of ophthalmologist and the cell sheet manufacturer for corneal regenerative medicine was successfully obtained as digital data contents. Since these digital data contents are easy to use for non-experts, we strongly expect the dissemination of corneal regenerative medicine using cell sheet in the near future. We will forward this project in terms of 2013.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る